Posted by Michael Wonder on 30 Jun 2021
European Commission approves Merck’s Keytruda (pembrolizumab) plus chemotherapy for certain patients with oesophageal cancer or HER2 negative gastro-oesophageal junction adenocarcinoma
29 June 2021 - Keytruda is first anti-PD-1 therapy approved in Europe in combination with chemotherapy for first-line treatment of advanced oesophageal or GEJ cancer, regardless of histology.
Merck today announced that the European Commission has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or human epidermal growth factor receptor 2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 (combined positive score ≥10).
